These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 17827967

  • 1. CXCL11 (Interferon-inducible T-cell alpha chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated with methylprednisolone.
    Szczuciński A, Kalinowska A, Losy J.
    Eur Neurol; 2007; 58(4):228-32. PubMed ID: 17827967
    [Abstract] [Full Text] [Related]

  • 2. CCL5, CXCL10 and CXCL11 chemokines in patients with active and stable relapsing-remitting multiple sclerosis.
    Szczuciński A, Losy J.
    Neuroimmunomodulation; 2011; 18(1):67-72. PubMed ID: 20720435
    [Abstract] [Full Text] [Related]

  • 3. Effect of treatment with methylprednisolone on the serum levels of IL-12, IL-10 and CCL2 chemokine in patients with multiple sclerosis in relapse.
    Rentzos M, Nikolaou C, Rombos A, Evangelopoulos ME, Kararizou E, Koutsis G, Zoga M, Dimitrakopoulos A, Tsoutsou A, Sfangos C.
    Clin Neurol Neurosurg; 2008 Dec; 110(10):992-6. PubMed ID: 18657352
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of high-dose methylprednisolone treatment on Th17 cells in patients with multiple sclerosis in relapse.
    Liu M, Hu X, Wang Y, Peng F, Yang Y, Chen X, Lu Z, Zheng X.
    Acta Neurol Scand; 2009 Oct; 120(4):235-41. PubMed ID: 19769778
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Steroid therapy altered serum levels of CCL2 and CCL5 chemokines in multiple sclerosis patients during relapse.
    Bartosik-Psujek H, Stelmasiak Z.
    Eur Neurol; 2004 Oct; 52(4):237-41. PubMed ID: 15550762
    [Abstract] [Full Text] [Related]

  • 11. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid.
    Mellergård J, Edström M, Vrethem M, Ernerudh J, Dahle C.
    Mult Scler; 2010 Feb; 16(2):208-17. PubMed ID: 20007431
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Change of interleukin-4 and interleukin-12 levels after therapy of multiple sclerosis relapse with methylprednisolone].
    Bartosik-Psujek H, Magryś A, Montewka-Kozioł M, Stelmasiak Z.
    Neurol Neurochir Pol; 2005 Feb; 39(3):207-12. PubMed ID: 15981158
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication.
    Festoff BW, Li C, Woodhams B, Lynch S.
    J Neurol Sci; 2012 Dec 15; 323(1-2):61-5. PubMed ID: 22967748
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis.
    Cepok S, Schreiber H, Hoffmann S, Zhou D, Neuhaus O, von Geldern G, Hochgesand S, Nessler S, Rothhammer V, Lang M, Hartung HP, Hemmer B.
    Arch Neurol; 2009 Oct 15; 66(10):1216-23. PubMed ID: 19667211
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.